Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 2Glioblastoma 2Cholangiocarcinoma 2Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Leukemia, Myeloid, Acute 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 15Radiotherapy 11Everolimus 6Bevacizumab 6Irinotecan 5Cyclophosphamide 5ribociclib 4Radiation 4Panobinostat 4TIC10 compound 3Specimen Handling 3Re-Irradiation 3Etoposide 3Dasatinib 3pembrolizumab 2nimotuzumab 2abemaciclib 2Vorinostat 2Valproic Acid 2Topotecan 2Nivolumab 2Mebendazole 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2GDC-0084 2Erlotinib Hydrochloride 2Diphtheria-Tetanus Vaccine 2Cilengitide 2Cetuximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diffuse Intrinsic Pontine Glioma × olutasidenib × CNS × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡